X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orotecan (irinotecan HCl) is a topoisomerase-I inhibitor approved by the FDA. It is now being evaluated for the treatment of recurrent pediatric solid tumors.
Lead Product(s): Irinotecan Hydrochloride,Temozolomide
Therapeutic Area: Oncology Product Name: Orotecan
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
Edison Oncology Holding Corp. has transferred certain rights to novel DNA-damage response inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc.
Lead Product(s): EO2000
Therapeutic Area: Oncology Product Name: EO2000
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rakovina Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2021
Details:
Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
Lead Product(s): EO1001
Therapeutic Area: Oncology Product Name: EO1001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apollomics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
